Compare NTNX & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | ARWR |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.3B |
| IPO Year | 2015 | 2009 |
| Metric | NTNX | ARWR |
|---|---|---|
| Price | $45.23 | $75.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 10 |
| Target Price | $62.29 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 2.8M | 1.7M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 227.45 | 99.80 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,537,927,000.00 | $16,142,321.00 |
| Revenue This Year | $13.44 | N/A |
| Revenue Next Year | $13.03 | N/A |
| P/E Ratio | $84.95 | ★ N/A |
| Revenue Growth | ★ 18.11 | N/A |
| 52 Week Low | $34.01 | $14.30 |
| 52 Week High | $82.42 | $82.26 |
| Indicator | NTNX | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 53.86 |
| Support Level | $35.23 | $70.79 |
| Resistance Level | $53.75 | $76.45 |
| Average True Range (ATR) | 1.67 | 4.05 |
| MACD | 0.19 | -0.69 |
| Stochastic Oscillator | 47.85 | 43.70 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.